The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis in the golden hamster model

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 40, Issue 6, 2007, Pages 627-630

  Sinagra, Ángel ^a   Luna, Concepción ^a   Abraham, David ^b   Iannella, Maria Del Carmen ^c   Riarte, Adelina ^a   Krolewiecki, Alejandro J ^d,e,f  

^a Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d FUNDACIÓN HUÉSPED   (Argentina)

^e UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^f Pasaje Peluffo 3932   (Argentina)

Author keywords

Azithromycin; Hamster; Leishmania Leishmania amazonensis; Leishmania Viannia braziliensis

Indexed keywords

AZITHROMYCIN; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG SCREENING; FEMALE; FOOT PAD; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MALE; NONHUMAN; PARASITE; PROMASTIGOTE; SYRIAN HAMSTER; THICKNESS;

ANIMALIA; CRICETINAE; LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; MESOCRICETUS AURATUS;

EID: 38349083201     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822007000600005     Document Type: Article

References (16)

1. Daoud S, Boushi L. Azithromycin, ineffective in the treatment of old-world cutaneous leishmaniasis. International Journal of Dermatology 45: 1126-1128, 2006.
2. Figueiredo EM, Silva JC, Brazil RP. Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis. Revista da Sociedade Brasileira de Medicina Tropical 32: 191-193, 1999.
3. Frank FM, Fernandez MM, Taranto NJ, Cajal SP, Margni RA, Castro E, Thomaz-Soccol V, Malchiodi EL. Characterization of human infection by Leishmania spp. in the Northwest of Argentina: immune response, double infection with Trypanosoma cruzi and species of Leishmania involved. Parasitology 126: 31-39, 2003.
4. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. American Journal of Respiratory and Critical Care Medicine 168: 121-125, 2003.
5. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33: 277-282, 1989.
6. Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against Leishmania major in vitro and in vivo. The American Journal of Tropical Medicine and Hygiene 67: 273-277, 2002.
7. Krolewiecki A, Scott P, Abraham D. The anti-Leishmania activity of azithromycin in an in-vitro model. Revista da Sociedade Brasileira de Medicina Tropical 32: 137, 1999.
8. Marco JD, Barroso PA, Calvopiña M, Kumazawa H, Furuya M, Korenaga M, Cajal SP, Mora MC, Rea MMJ, Borda CE, Basombrío MA, Taranto NJ, Hashiguchi Y. Species assignation of Leishmania from human and canine American tegumentary leishmaniasis cases by multilocus enzyme electrophoresis in North Argentina. The American Journal of Tropical Medicine and Hygiene 72: 606-611, 2005.
9. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistance Updates 7: 257-266, 2004.
10. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, Paula EV, Pimenta Junior FG, Giraldo LER. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 36: 65-69, 2003.
11. Schubach A, Marzochi MCA, Cuzzi-Maya T, Oliveira AV, Araújo ML, Oliveira ALC, Pacheco RS, Momen H, Conceicao-Silva F, Coutinho SG, Marzochi KBF. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. The American Journal Tropical Medicine and Hygiene 58: 824-827, 1998.
12. Silva-Vergara ML, Almeida-Silva L, Maneira FRZ, Silva AG, Prata A. Azithromycin in the treatment of mucosal leishmaniasis. Revista do Instituto de Medicina Tropical de Sao Paulo 46: 175-177, 2004.
13. Sinagra A, Riarte A, Luna C, Campanini A, Segura EL. Leishmania (Viannia) braziliensis: biological behavior in golden hamsters of isolates from Argentine patients. The American Journal of Tropical Medicine and Hygiene 57: 115-118, 1997.
14. Sivapalasingam S, Steigbigel N. Macrolides, clindamycin and ketolides, In: Mandell G, Bennett J, Dolin R (eds) Principles and Practice of Infectious Diseases, Elsevier Churchill Livingstone: Philadelphia, PA 396-417, 2005.
15. Travi BL, Martinez JE, Zea A. Antimonial treatment of hamsters infected with Leishmania (Viannia) panamensis: assessment of parasitological cure with different therapeutic schedules. Transactions of the Royal Society of Tropical Medicine and Hygiene 87: 567-569, 1993.
16. Xu G, Fujita J, Negayama K, Yuube K, Hojo S, Yamaji Y, Kawanishi K, Takahara J. Effect of macrolide antibiotics on macrophage functions. Microbiology & Immunology 40: 473-479, 1996.